INTERLEUKIN 2 (HUMAN)
Melanoma
Hospital Italiano de Buenos Airesprotein_peptideEarly Phase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 65/ 100
Competitive context
329 Active assets in the Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE Suzhou BlueHorse Therapeutics Co., Ltd. | Phase 3 | BB |
Cyclophosphamide Primmune Therapeutics, Inc. | Phase 4 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
Epirubicin Primmune Therapeutics, Inc. | Phase 4 | BB |
Pembrolizumab Biocon Biologics UK PLC | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →